Caution should be taken in the methodology used to confirm c.156-157insAlu BRCA2 mutation

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 617-618

  MacHado, Patricia ^a   Vaz, Fatima ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA;

ALU SEQUENCE; BREAST CANCER; CANCER RISK; EXON; FAMILY; GENE MUTATION; GENE REARRANGEMENT; GENETIC RISK; GENETIC SCREENING; HETEROZYGOTE; HUMAN; LETTER; OVARY CANCER; PORTUGAL; PRIORITY JOURNAL; BREAST TUMOR; FEMALE; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; MUTATION; NOTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BRCA2 PROTEIN; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 70349568360     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0124-0     Document Type: Letter

References (10)

1. Peixoto A, Santos C, Rocha P et al (2008) The c.156-157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat (Mar):25 (Epub ahead of print)
2. Machado PM, Brandao RD, Cavaco BM et al (2007) Screening for a BRCA2 rearrangement in high-risk rearrangement in highrisk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol 25:2027-2034. doi:10.1200/JCO.2006.06.9443
3. Teugels E, De Brakeleer S, Goelen G et al (2005) De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat 26:284. doi:10.1002/humu.9366
4. Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al (2007) Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5035-5036. doi:10.1200/JCO.2007.13.4346
5. Santarosa M, Viel A, Boiocchi M (1999) Splice variant lacking the transactivation domain of the BRCA2 gene and mutations in the splice acceptor site of intron 2. Genes Chromosomes Cancer 26:381-382. doi:10.1002/(SICI)1098- 2264(199912)26:4\381::AID-GCC14[3.0.CO;2-N
6. Zou J, Hirose Y, Siddique H et al (1999) Structure and expression of variant BRCA2a lacking the transactivation domain. Oncol Rep 6:437-440
7. Speevak MD, Young SS, Feilotter H et al (2003) Alternatively spliced, truncated human BRCA2 isoforms contain a novel coding exon. Eur J Hum Genet 11:951-954. doi:10.1038/sj.ejhg.5201063
8. Koul A, Nilbert M, Borg A (1999) A somatic mutation in RER endomentrial carcinomas that specifically deletes the amino-terminal transactivation domain. Genes Chromosomes Cancer 24:207-212. doi:10.1002/(SICI)1098-2264(199903)24: 3<207::AID-GCC5>3.0.CO;2-3
9. Machado PM, Cavaco BM, Brandao RD et al (2007) In reply to: Díez O, Gutiérrez-Enríquez S, Ramón y Cajal T et al. Caution should be used when interpreting alterations affecting the exon 3 of the BRCA2 gene in breast/ovarian cancer families. J Clin Oncol 25:5036-5038. doi:10.1200/JCO.2007.13.5442
10. Nordling M, Karlsson P, Wahlstrom J et al (1998) A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58:1372-1375